DIAGNOS Inc. (CVE:ADK – Get Free Report) was down 4.5% on Monday. The company traded as low as C$0.31 and last traded at C$0.32. Approximately 106,000 shares were traded during mid-day trading, a decline of 53% from the average session volume of 223,863 shares. The stock had previously closed at C$0.33.
DIAGNOS Price Performance
The stock has a market capitalization of C$38.13 million, a price-to-earnings ratio of -7.88 and a beta of 0.05. The company has a debt-to-equity ratio of 204.05, a quick ratio of 0.68 and a current ratio of 1.49. The company has a fifty day simple moving average of C$0.42 and a two-hundred day simple moving average of C$0.31.
Insider Activity
In related news, Director Robert Dunn purchased 105,000 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were bought at an average price of C$0.48 per share, for a total transaction of C$50,400.00. Following the completion of the transaction, the director owned 2,679,920 shares of the company’s stock, valued at approximately C$1,286,361.60. This trade represents a 4.08% increase in their ownership of the stock. Company insiders own 16.81% of the company’s stock.
About DIAGNOS
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence.
Further Reading
- Five stocks we like better than DIAGNOS
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for DIAGNOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DIAGNOS and related companies with MarketBeat.com's FREE daily email newsletter.
